AU2001280135A1 - Fibrinogen lowering agents - Google Patents

Fibrinogen lowering agents

Info

Publication number
AU2001280135A1
AU2001280135A1 AU2001280135A AU8013501A AU2001280135A1 AU 2001280135 A1 AU2001280135 A1 AU 2001280135A1 AU 2001280135 A AU2001280135 A AU 2001280135A AU 8013501 A AU8013501 A AU 8013501A AU 2001280135 A1 AU2001280135 A1 AU 2001280135A1
Authority
AU
Australia
Prior art keywords
lowering agents
fibrinogen
fibrinogen lowering
agents
lowering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001280135A
Other languages
English (en)
Inventor
Masao Hirakata
Yoshimi Imura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU2001280135A1 publication Critical patent/AU2001280135A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001280135A 2000-08-25 2001-08-24 Fibrinogen lowering agents Abandoned AU2001280135A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000260881 2000-08-25
JP2000-260881 2000-08-25
PCT/JP2001/007239 WO2002015935A1 (fr) 2000-08-25 2001-08-24 Agents de reduction du fibrinogene

Publications (1)

Publication Number Publication Date
AU2001280135A1 true AU2001280135A1 (en) 2002-03-04

Family

ID=18748822

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001280135A Abandoned AU2001280135A1 (en) 2000-08-25 2001-08-24 Fibrinogen lowering agents

Country Status (5)

Country Link
US (1) US20030187038A1 (fr)
EP (1) EP1312379A4 (fr)
AU (1) AU2001280135A1 (fr)
CA (1) CA2420055C (fr)
WO (1) WO2002015935A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007964A1 (fr) * 2001-07-18 2003-01-30 Nippon Kayaku Kabushiki Kaisha Remede ou agent preventif de cardiopathie ou d'anevrysme contenant un compose d'inhibition de la chymase
CA2468827A1 (fr) * 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Agents pour ameliorer l'etat de resistance a l'insuline
CA2479722A1 (fr) * 2002-03-18 2003-10-02 Pharmacia Corporation Combinaison d'un antagoniste de recepteur d'aldosterone et de derive d'acide fibrique
AU2003209851A1 (en) * 2002-03-20 2003-09-29 The University Of Queensland Method of treatment and/or prophylaxis
CA2511737A1 (fr) * 2002-12-27 2004-07-22 Takeda Pharmaceutical Company Limited Inhibiteur de prise de poids corporel
JP4585198B2 (ja) * 2002-12-27 2010-11-24 武田薬品工業株式会社 体重増加抑制剤
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
DE10319592A1 (de) * 2003-05-02 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Behandlung von diabetischer Retinopathie mit Angiotensin II-Rezeptorblockern
US20050038093A1 (en) * 2003-05-02 2005-02-17 Boehringer Ingelheim International Gmbh Treating diabetic retinopathy with angiotensin II receptor blockers
KR20060056352A (ko) * 2003-07-31 2006-05-24 니콕스 에스. 에이. 안지오텐신ⅱ 수용체 차단제 유도체들
EP1666067A4 (fr) * 2003-08-22 2009-07-22 Teijin Pharma Ltd Medicament contenant un inhibiteur de chymase en tant qu'agent actif
PE20050596A1 (es) * 2003-12-19 2005-10-18 Novartis Ag Microemulsion que comprende un inhibidor renina
EP1711168A2 (fr) * 2004-01-23 2006-10-18 Ranbaxy Laboratories Limited Compositions pharmaceutiques orales de candesartan cilexetil
AR048431A1 (es) 2004-03-17 2006-04-26 Novartis Ag Formulaciones galenicas de compuestos organicos
US20080161321A1 (en) * 2004-03-17 2008-07-03 David Louis Feldman Use of Renin Inhibitors in Therapy
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
CA2583768A1 (fr) * 2004-10-07 2006-04-13 Takeda Pharmaceutical Company Limited Agent pour le traitement prophylactique ou therapeutique d'un syndrome metabolique
TW202404601A (zh) * 2022-04-05 2024-02-01 加拿大商索科普拉健康與人類科學兩合公司 用於選擇性消退血栓性或血栓栓塞性疾病中血栓的凝乳酶抑制劑

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US612523A (en) * 1898-10-18 Piano-truck
CA2115985A1 (fr) * 1993-02-25 1994-08-26 Kohei Nishikawa Inhibiteur de l'hypertrophie vasculaire
AU696868B2 (en) * 1994-03-29 1998-09-17 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin II receptor blocking imidazoles
US5658936A (en) * 1995-09-18 1997-08-19 Brigham & Women's Hospital, Inc. Enhancement of erectile function with renin-angiotensin system inhibitors
ATE225657T1 (de) * 1995-10-06 2002-10-15 Novartis Erfind Verwalt Gmbh Ati-rezeptorantagonisten zur verhinderung und behandlung des postischemischen nervenversagens und zum schutze ischemischer nieren
BR9908474A (pt) * 1998-03-04 2000-12-05 Takeda Chemical Industries Ltd Preparação de liberação prolongada, processo para a produção de uma preparação de liberação prolongada, e, composição farmacêutica
US6248729B1 (en) * 1998-06-17 2001-06-19 Bristol-Myers Squibb Co. Combination of an ADP-receptor blocking antiplatelet drug and antihypertensive drug and a method for preventing a cerebral infarction employing such combination

Also Published As

Publication number Publication date
US20030187038A1 (en) 2003-10-02
WO2002015935A1 (fr) 2002-02-28
EP1312379A1 (fr) 2003-05-21
CA2420055A1 (fr) 2003-01-31
EP1312379A4 (fr) 2004-08-25
CA2420055C (fr) 2010-06-01

Similar Documents

Publication Publication Date Title
AU2002221601A1 (en) Disinfectant
AU2001262847A1 (en) Language-understanding
AU2002225730A1 (en) Compounds
AU2001288040A1 (en) Homeostasis-maintaining agents
AU2002214284A1 (en) Anti-helicobacterial agents
AU2000267458A1 (en) Hypercomputer
AU2001254546A1 (en) Aminopiperidines
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001220246A1 (en) Neckphone
AU2001280135A1 (en) Fibrinogen lowering agents
EP1151667A3 (fr) Agent d'activation de plantes
AUPQ661800A0 (en) Insulin-potentiating compounds
AU2001265871A1 (en) Substituted sulfonylaminopyrimidines
AU2001258924A1 (en) Microsatellite-aflp
AU2001254731A1 (en) Substituted phenyluracils
AU2001258255A1 (en) Substituted benzoylcyclohexenones
AU2002225724A1 (en) Motilide compounds
AU2002217285A1 (en) Compounds
AU2001246864A1 (en) Hypotensors
AU2001226668A1 (en) Crankshaft-starter-generator
AU2001260192A1 (en) Glycinamides
AU2001262711A1 (en) Cytoprotectors
AU4859301A (en) Antihistaminic compounds
AU2002223604A1 (en) Substituted phenyluracils
AU2001274683A1 (en) Contrast agents